CD44 Glycosylation as a Therapeutic Target in Oncology

The interaction of non-kinase transmembrane glycoprotein CD44 with ligands including hyaluronic acid (HA) is closely related to the occurrence and development of tumors. Changes in CD44 glycosylation can regulate its binding to HA, Siglec-15, fibronectin, TM4SF5, PRG4, FGF2, collagen and podoplanin...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Chengcheng, Wang, Qian, An, Jiaxing, Chen, Jie, Li, Xiaolan, Long, Qian, Xiao, Linlin, Guan, Xiaoyan, Liu, Jianguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351704/
https://www.ncbi.nlm.nih.gov/pubmed/35936713
http://dx.doi.org/10.3389/fonc.2022.883831
_version_ 1784762491727773696
author Liao, Chengcheng
Wang, Qian
An, Jiaxing
Chen, Jie
Li, Xiaolan
Long, Qian
Xiao, Linlin
Guan, Xiaoyan
Liu, Jianguo
author_facet Liao, Chengcheng
Wang, Qian
An, Jiaxing
Chen, Jie
Li, Xiaolan
Long, Qian
Xiao, Linlin
Guan, Xiaoyan
Liu, Jianguo
author_sort Liao, Chengcheng
collection PubMed
description The interaction of non-kinase transmembrane glycoprotein CD44 with ligands including hyaluronic acid (HA) is closely related to the occurrence and development of tumors. Changes in CD44 glycosylation can regulate its binding to HA, Siglec-15, fibronectin, TM4SF5, PRG4, FGF2, collagen and podoplanin and activate or inhibit c-Src/STAT3/Twist1/Bmi1, PI3K/AKT/mTOR, ERK/NF-κB/NANOG and other signaling pathways, thereby having a profound impact on the tumor microenvironment and tumor cell fate. However, the glycosylation of CD44 is complex and largely unknown, and the current understanding of how CD44 glycosylation affects tumors is limited. These issues must be addressed before targeted CD44 glycosylation can be applied to treat human cancers.
format Online
Article
Text
id pubmed-9351704
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93517042022-08-05 CD44 Glycosylation as a Therapeutic Target in Oncology Liao, Chengcheng Wang, Qian An, Jiaxing Chen, Jie Li, Xiaolan Long, Qian Xiao, Linlin Guan, Xiaoyan Liu, Jianguo Front Oncol Oncology The interaction of non-kinase transmembrane glycoprotein CD44 with ligands including hyaluronic acid (HA) is closely related to the occurrence and development of tumors. Changes in CD44 glycosylation can regulate its binding to HA, Siglec-15, fibronectin, TM4SF5, PRG4, FGF2, collagen and podoplanin and activate or inhibit c-Src/STAT3/Twist1/Bmi1, PI3K/AKT/mTOR, ERK/NF-κB/NANOG and other signaling pathways, thereby having a profound impact on the tumor microenvironment and tumor cell fate. However, the glycosylation of CD44 is complex and largely unknown, and the current understanding of how CD44 glycosylation affects tumors is limited. These issues must be addressed before targeted CD44 glycosylation can be applied to treat human cancers. Frontiers Media S.A. 2022-07-21 /pmc/articles/PMC9351704/ /pubmed/35936713 http://dx.doi.org/10.3389/fonc.2022.883831 Text en Copyright © 2022 Liao, Wang, An, Chen, Li, Long, Xiao, Guan and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Liao, Chengcheng
Wang, Qian
An, Jiaxing
Chen, Jie
Li, Xiaolan
Long, Qian
Xiao, Linlin
Guan, Xiaoyan
Liu, Jianguo
CD44 Glycosylation as a Therapeutic Target in Oncology
title CD44 Glycosylation as a Therapeutic Target in Oncology
title_full CD44 Glycosylation as a Therapeutic Target in Oncology
title_fullStr CD44 Glycosylation as a Therapeutic Target in Oncology
title_full_unstemmed CD44 Glycosylation as a Therapeutic Target in Oncology
title_short CD44 Glycosylation as a Therapeutic Target in Oncology
title_sort cd44 glycosylation as a therapeutic target in oncology
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351704/
https://www.ncbi.nlm.nih.gov/pubmed/35936713
http://dx.doi.org/10.3389/fonc.2022.883831
work_keys_str_mv AT liaochengcheng cd44glycosylationasatherapeutictargetinoncology
AT wangqian cd44glycosylationasatherapeutictargetinoncology
AT anjiaxing cd44glycosylationasatherapeutictargetinoncology
AT chenjie cd44glycosylationasatherapeutictargetinoncology
AT lixiaolan cd44glycosylationasatherapeutictargetinoncology
AT longqian cd44glycosylationasatherapeutictargetinoncology
AT xiaolinlin cd44glycosylationasatherapeutictargetinoncology
AT guanxiaoyan cd44glycosylationasatherapeutictargetinoncology
AT liujianguo cd44glycosylationasatherapeutictargetinoncology

Ejemplares similares